Switch theme
Sign up to access all valuation multiples
SK Biopharmaceuticals Co Ltd is a pharmaceutical company engaged in research and development of new drugs for treatment of central nervous system (CNS) disorders. The company is also researching for the development of drugs to treat brain tumors, including metastatic tumors. It has a Bio Science Research Institute in Pangyo Techno Valley in Gyeonggi Province. Its drugs in pipeline include Cenobamate, Solriamfetol, Carisbamate, Relenopride, SKL13865, SKL20540, SKL-PSY, and SKL24741.
2011
n/a
LTM Revenue $442M
LTM EBITDA $97.9M
$5.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
SK Biopharmaceuticals has a last 12-month revenue (LTM) of $442M and a last 12-month EBITDA of $97.9M.
In the most recent fiscal year, SK Biopharmaceuticals achieved revenue of $398M and an EBITDA of $73.2M.
SK Biopharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See SK Biopharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $442M | XXX | $398M | XXX | XXX | XXX |
| Gross Profit | $407M | XXX | $367M | XXX | XXX | XXX |
| Gross Margin | 92% | XXX | 92% | XXX | XXX | XXX |
| EBITDA | $97.9M | XXX | $73.2M | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 18% | XXX | XXX | XXX |
| EBIT | $83.7M | XXX | $70.0M | XXX | XXX | XXX |
| EBIT Margin | 19% | XXX | 18% | XXX | XXX | XXX |
| Net Profit | $142M | XXX | $175M | XXX | XXX | XXX |
| Net Margin | 32% | XXX | 44% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, SK Biopharmaceuticals's stock price is KRW 93000 (or $68).
SK Biopharmaceuticals has current market cap of KRW 7.28T (or $5.3B), and EV of KRW 7.14T (or $5.2B).
See SK Biopharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.2B | $5.3B | XXX | XXX | XXX | XXX | $1.84 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, SK Biopharmaceuticals has market cap of $5.3B and EV of $5.2B.
SK Biopharmaceuticals's trades at 13.0x EV/Revenue multiple, and 70.9x EV/EBITDA.
Equity research analysts estimate SK Biopharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
SK Biopharmaceuticals has a P/E ratio of 37.2x.
See valuation multiples for SK Biopharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.3B | XXX | $5.3B | XXX | XXX | XXX |
| EV (current) | $5.2B | XXX | $5.2B | XXX | XXX | XXX |
| EV/Revenue | 11.7x | XXX | 13.0x | XXX | XXX | XXX |
| EV/EBITDA | 53.0x | XXX | 70.9x | XXX | XXX | XXX |
| EV/EBIT | 62.0x | XXX | 74.1x | XXX | XXX | XXX |
| EV/Gross Profit | 12.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 37.2x | XXX | 30.3x | XXX | XXX | XXX |
| EV/FCF | 41.6x | XXX | 87.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSK Biopharmaceuticals's last 12 month revenue growth is 28%
SK Biopharmaceuticals's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
SK Biopharmaceuticals's rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
SK Biopharmaceuticals's rule of X is 91% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for SK Biopharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 28% | XXX | 28% | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Growth | 68% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 22% | XXX | 46% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 91% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 29% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 75% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SK Biopharmaceuticals acquired XXX companies to date.
Last acquisition by SK Biopharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . SK Biopharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was SK Biopharmaceuticals founded? | SK Biopharmaceuticals was founded in 2011. |
| Where is SK Biopharmaceuticals headquartered? | SK Biopharmaceuticals is headquartered in South Korea. |
| Who is the CEO of SK Biopharmaceuticals? | SK Biopharmaceuticals's CEO is Mr. Dong-Hoon Lee. |
| Is SK Biopharmaceuticals publicy listed? | Yes, SK Biopharmaceuticals is a public company listed on KRX. |
| What is the stock symbol of SK Biopharmaceuticals? | SK Biopharmaceuticals trades under 326030 ticker. |
| When did SK Biopharmaceuticals go public? | SK Biopharmaceuticals went public in 2020. |
| Who are competitors of SK Biopharmaceuticals? | Similar companies to SK Biopharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of SK Biopharmaceuticals? | SK Biopharmaceuticals's current market cap is $5.3B |
| What is the current revenue of SK Biopharmaceuticals? | SK Biopharmaceuticals's last 12 months revenue is $442M. |
| What is the current revenue growth of SK Biopharmaceuticals? | SK Biopharmaceuticals revenue growth (NTM/LTM) is 28%. |
| What is the current EV/Revenue multiple of SK Biopharmaceuticals? | Current revenue multiple of SK Biopharmaceuticals is 11.7x. |
| Is SK Biopharmaceuticals profitable? | Yes, SK Biopharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of SK Biopharmaceuticals? | SK Biopharmaceuticals's last 12 months EBITDA is $97.9M. |
| What is SK Biopharmaceuticals's EBITDA margin? | SK Biopharmaceuticals's last 12 months EBITDA margin is 22%. |
| What is the current EV/EBITDA multiple of SK Biopharmaceuticals? | Current EBITDA multiple of SK Biopharmaceuticals is 53.0x. |
| What is the current FCF of SK Biopharmaceuticals? | SK Biopharmaceuticals's last 12 months FCF is $125M. |
| What is SK Biopharmaceuticals's FCF margin? | SK Biopharmaceuticals's last 12 months FCF margin is 28%. |
| What is the current EV/FCF multiple of SK Biopharmaceuticals? | Current FCF multiple of SK Biopharmaceuticals is 41.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
